Osteopontin expression in cardiomyocytes induces dilated cardiomyopathy

Circulation: Heart Failure

Volumn 3, Issue 3, 2010, Pages 431-439

  Renault, Marie Ange ^a   Robbesyn, Fanny ^a   Réant, Patricia ^a,b   Douin, Victorine ^a,c   Daret, Danièle ^a,b   Allières, Cécile ^a,b   Belloc, Isabelle ^a,b   Couffinhal, Thierry ^a   Arnal, Jean François ^a,c   Klingel, Karin ^d   Desgranges, Claude ^a,b   Santos, Pierre Dos ^a,b   Charpentier, Flavien ^e,f,g   Gadeau, Alain Pierre ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e L INSTITUT DU THORAX   (France)

^f UNIVERSITÉ DE NANTES   (France)

^g CNRS   (France)

Author keywords

Heart disease; Heart failure; Immune system; Inflammation; Myocarditis

Indexed keywords

CARDIAC MYOSIN; MYOSIN HEAVY CHAIN ALPHA; OSTEOPONTIN; TROPONIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CYTOTOXICITY; ECHOGRAPHY; HALF LIFE TIME; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; INFLAMMATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PREMATURITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTOLIC DYSFUNCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; FIBROSIS; HEART FAILURE; LYMPHOCYTE ACTIVATION; METABOLISM; MYOCARDITIS; NEUTROPHIL CHEMOTAXIS; PATHOLOGY;

ANIMALS; CARDIOMYOPATHY, DILATED; DISEASE MODELS, ANIMAL; FIBROSIS; HEART FAILURE; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; MYOCARDITIS; MYOCYTES, CARDIAC; NEUTROPHIL INFILTRATION; OSTEOPONTIN;

EID: 77954731192     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.898114     Document Type: Article

References (27)

1. Heart Failure Society Of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:e1-e2.
2. Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360:1526-1538.
3. Afanasyeva M, Georgakopoulos D, Rose NR. Autoimmune myocarditis: cellular mediators of cardiac dysfunction. Autoimmun Rev. 2004;3: 476-486.
4. Mason JW. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res. 2003;60:5-10.
5. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107: 1055-1061.
6. Lam Shang Leen L, Filipe C, Billon A, Garmy-Susini B, Jalvy S, Robbesyn F, Daret D, Allieres C, Rittling SR, Werner N, Nickenig G, Deutsch U, Duplaa C, Dufourcq P, Lenfant F, Desgranges C, Arnal JF, Gadeau AP. Estrogen-stimulated endothelial repair requires osteopontin. Arterioscler Thromb Vasc Biol. 2008;28:2131-2136.
7. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2302-2309.
8. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287:860-864.
9. O'Regan AW, Hayden JM, Berman JS. Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol. 2000;68:495-502.
10. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol. 2007;8:74-83.
11. Singh K, Sirokman G, Communal C, Robinson KG, Conrad CH, Brooks WW, Bing OH, Colucci WS. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension. 1999;33: 663-670.
12. Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fleck E, Hsueh WA. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation. 1997;96:3063-3071.
13. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest. 1998;101:1468-1478.
14. Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K. Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy. Eur J Heart Fail. 2005;7: 755-762.
15. Szalay G, Sauter M, Haberland M, Zuegel U, Steinmeyer A, Kandolf R, Klingel K. Osteopontin: a fibrosis-Related Marker Molecule in Cardiac Remodeling of Enterovirus Myocarditis in the Susceptible Host. Circ Res. 2009;104:851-859.
16. Royer A, van Veen TA, Le Bouter S, Marionneau C, Griol-Charhbili V, Leoni AL, Steenman M, van Rijen HV, Demolombe S, Goddard CA, Richer C, Escoubet B, Jarry-Guichard T, Colledge WH, Gros D, de Bakker JM, Grace AA, Escande D, Charpentier F. Mouse model of SCN5A-linked hereditary Lenegre's disease: age-related conduction slowing and myocardial fibrosis. Circulation. 2005;111:1738-1746.
17. Mitchell GF, Jeron A, Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol. 1998;274:H747-H751.
18. Keller DI, Coirault C, Rau T, Cheav T, Weyand M, Amann K, Lecarpentier Y, Richard P, Eschenhagen T, Carrier L. Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol. 2004;36: 355-362.
19. Kruger M, Pfitzer G, Stehle R. Expression and purification of human cardiac troponin subunits and their functional incorporation into isolated cardiac mouse myofibrils. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;786:287-296.
20. Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakizaki M, Dohmae N, Yoshie O, Imai T. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol. 2002;168:6173-6180.
21. Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol. 1987;139:3630-3636.
22. Kaya Z, Goser S, Buss SJ, Leuschner F, Ottl R, Li J, Volkers M, Zittrich S, Pfitzer G, Rose NR, Katus HA. Identification of cardiac troponin I sequence motifs leading to heart failure by induction of myocardial inflammation and fibrosis. Circulation. 2008;118:2063-2072.
23. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg JR, Steinman L. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294:1731-1735.
24. Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A, Giannitsis E, Katus H, Frey N. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail. 2008;1:43-49.
25. O'Regan AW, Chupp GL, Lowry JA, Goetschkes M, Mulligan N, Berman JS. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol. 1999;162:1024-1031.
26. Hanawa H, Abe S, Hayashi M, Yoshida T, Yoshida K, Shiono T, Fuse K, Ito M, Tachikawa H, Kashimura T, Okura Y, Kato K, Kodama M, Maruyama S, Yamamoto T, Aizawa Y. Time course of gene expression in rat experimental autoimmune myocarditis. Clin Sci (Lond). 2002;103: 623-632.
27. Abel B, Kurrer M, Shamshiev A, Marty RR, Eriksson U, Gunthert U, Kopf M. The osteopontin-CD44 pathway is superfluous for the development of autoimmune myocarditis. Eur J Immunol. 2006; 36:494-499.